The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | The role of PI3K inhibitors in CLL
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the status of PI3K inhibitors, such as idelalisib and duvelisib, in the treatment of chronic lymphocytic leukemia (CLL). Despite their role as treatments for patients with CLL who have progressed on BTK inhibitors and venetoclax, limited data exists for PI3K inhibitors in this patient setting. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
